TD Cowen assumed coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a research report report published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $31.00 price target on the stock.
Separately, William Blair began coverage on shares of CeriBell in a report on Tuesday. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.00.
Check Out Our Latest Analysis on CBLL
CeriBell Trading Up 2.7 %
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
- Five stocks we like better than CeriBell
- Short Selling: How to Short a Stock
- AMD: The AI Disruptor – Is It Time to Follow Big Tech’s Lead?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Analysts Signal Big Upside: Top 3 Stocks to Watch Right Now
- Stock Splits, Do They Really Impact Investors?
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
